Article de revue
Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models
The phase 3 trial of the RTS,S/AS01 malaria vaccine candidate showed modest efficacy of the vaccine against Plasmodium falciparum malaria, but was not powered to assess mortality endpoints. Impact projections and cost-effectiveness estimates for longer timeframes than the trial follow-up and across a range of settings are needed to inform policy recommendations. We aimed to assess the public health impact and cost-effectiveness of routine use of the RTS,S/AS01 vaccine in African settings.
Auteurs
Langues
- Anglais
Année de publication
2016
Journal
The Lancet
Volume
10016
Type
Article de revue
Catégories
- Vaccins et dispositifs d'administration
Maladies
- Paludisme
Organisations
- La Foundation Bill et Melinda Gates
- Gavi, l'Alliance du vaccin
- PATH
- Organisation Mondiale de la Santé (OMS)
Mots-clés
- New vaccine introduction